Abstract
Several adjuvant chemotherapy regimens exist for the treatment of stage III colon cancer. In conjunction with the clinical data from randomized trials, cost-effectiveness studies might help to inform the selection of the optimal treatment regimen. In this review, the outcomes from randomized clinical trials and the elements and process of a cost-effectiveness analysis in this setting are discussed. In addition, the data from several published cost-effectiveness analysis studies in the adjuvant setting are reviewed. In general, capecitabine-based regimens have been found to be less costly and more effective than 5-fluorouracil-based regimens. The combination of oxaliplatin leads to a modestly improved effectiveness and at an acceptable incremental cost. Future studies using data obtained outside the setting of a clinical trial might help to further guide selection of the most cost-effective regimen.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 219-226 |
| Number of pages | 8 |
| Journal | Clinical colorectal cancer |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2015 |
| Externally published | Yes |
Keywords
- 5-Fluorouracil
- Capecitabine
- Cost-effectiveness analysis
- Oxaliplatin
- Pharmacoeconomics
- Stage III colon cancer
ASJC Scopus subject areas
- Oncology
- Gastroenterology
